Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Artificial pancreas Stories

2012-07-26 02:28:13

DANBURY, Conn., July 26, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH) has awarded Biodel a grant for the development of concentrated ultra-rapid-acting insulin formulations for use in an artificial pancreas, also known as a closed loop pump system. "We are gratified to receive this award recognizing our innovations in the development of novel therapies to treat diabetes,"...

2012-07-10 10:25:39

Newer technologies designed to help people with type 1 diabetes monitor their blood sugar levels daily work better than traditional methods and require fewer painful needle sticks, new Johns Hopkins research suggests. The research findings, published online in the July 10 issue of the Annals of Internal Medicine, suggest that even though these diabetic control technologies are more costly, people with diabetes who use an insulin pump are more satisfied with their treatment and quality of...

Diabetes Reversal In Mice Via Stem Cells
2012-06-28 11:41:14

Connie K. Ho for redOrbit.com — Your Universe Online Diabetes is a detrimental disease. In order to combat the illness, University of British Columbia (UBC) researchers conducted a study with an industry partner and discovered that stem cells can reverse Type 1 diabetes in mice. The discovery leads the way for the development of innovative treatments of diabetes, which is caused by deficient production of insulin by the pancreas. Insulin allows glucose to be held by the...

2012-06-18 02:26:46

PETACH TIKVAH, Israel, June 18, 2012 /PRNewswire/ -- Yet another exciting breakthrough took place yesterday in the advancement and development of the ARTIFICIAL PANCREAS by specialists at Schneider Children's Medical Center of Israel. For the first time ever, two patients with diabetes were successfully treated overnight in their own homes with the MD-Logic Artificial Pancreas (MD-Logic) system. This is a huge and major step towards the development of a commercial device...

'Sugar' New Energy Source For Future Medical Implants
2012-06-13 16:48:00

Implantable fuel cell built at MIT could power neural prosthetics that help patients regain control of limbs. MIT engineers have developed a fuel cell that runs on the same sugar that powers human cells: glucose. This glucose fuel cell could be used to drive highly efficient brain implants of the future, which could help paralyzed patients move their arms and legs again. The fuel cell, described in the June 12 edition of the journal PLoS ONE, strips electrons from glucose molecules to...

2012-06-12 14:24:43

JDRF-funded researchers from Oregon Health and Science University and Legacy Health discovered a method to stabilize liquid glucagon for automated pump delivery JDRF-funded researchers at Oregon Health & Science University (OHSU) and Legacy Health have discovered a liquid glucagon formulation that may be useable in standard diabetes pumps. Such a formulation could broaden the use of glucagon to help prevent hypoglycemia in people with type 1 diabetes (T1D) who are treated with insulin....

2012-06-11 10:24:08

--JDRF-funded research demonstrates the feasibility of a wearable artificial pancreas to control blood sugar levels in first outpatient study-- NEW YORK, June 11, 2012 /PRNewswire-USNewswire/ --JDRF, a global leader in type 1 diabetes(T1D) research, is pleased to announce that an outpatient study being conducted at multiple academic institutions has demonstrated the safety and feasibility of artificial pancreas (AP) device testing on an ambulatory basis. The research, funded by JDRF, was...

2012-06-11 02:26:20

WEST CHESTER, Pa., June 11, 2012 /PRNewswire/ -- Results from the first feasibility study of an advanced first-generation artificial pancreas system were presented today at the 72nd Annual American Diabetes Association Meeting in Philadelphia. Findings from the study indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System was able to automatically predict a rise and fall in blood glucose and correspondingly increase and/or decrease insulin delivery safely. The HHM System...

2012-06-09 06:21:34

PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented results from a Phase 4 study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. Interim data from this study indicate that pre-administration of Hylenex recombinant in the SAP provided a consistent ultrafast insulin action profile over the infusion set life that resulted in improved glucose...

2012-06-07 02:28:45

Joint JDRF-Helmsley Charitable Trust Sensor Initiative Seeks to Accelerate Technology Innovation to Improve Glucose Control FRANKLIN LAKES, N.J. and NEW YORK, June 7, 2012 /PRNewswire-USNewswire/ -- JDRF and BD (Becton, Dickinson and Company) (NYSE:BDX) today announced an extension of their existing collaboration focused on Type 1 diabetes (T1D) to accelerate the development of BD's proprietary glucose-sensing technology which has shown promise in providing very accurate and...